Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628308 | 1.00 | TRPV4 (0.35) | TRPV4CETPP2RX7KDM4ETRPA1 | |
| SCHEMBL16595482 | 0.86 | BCL2L1 (0.43) | — | |
| SCHEMBL30087636 | 0.83 | KCNN4 (0.41) | TRPV4KDM4ETRPA1 | |
| SCHEMBL161757 | 0.83 | CA1 (0.39) | TRPV4CETPP2RX7KDM4ETRPA1 | |
| SCHEMBL30628280 | 0.79 | RAB9A (0.42) | TRPV4KDM4ECA2 | |
| SCHEMBL3394893 | 0.79 | ALDH1A1 (0.48) | TRPV4KDM4EHDAC4 | |
| SCHEMBL17420409 | 0.79 | L3MBTL1 (0.42) | CETP | |
| SCHEMBL17420645 | 0.79 | RAB9A (0.42) | TRPV4KDM4ECA2 | |
| SCHEMBL1759981 | 0.79 | DGAT1 (0.41) | KDM4E | |
| SCHEMBL17765237 | 0.78 | SLC22A12 (0.35) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-106660991-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-9808451-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3166937-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2017-01-12 | — | — | US | disclosed |
| US-9499514-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | TRPV4 4693/4885CETP 4472/4885P2RX7 1671/4885 |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | TRPV4 4738/4885CETP 3437/4885P2RX7 4386/4885 |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | TRPV4 4738/4885CETP 3437/4885P2RX7 4386/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | TRPV4 4738/4885CETP 3437/4885P2RX7 4386/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | TRPV4 4738/4885CETP 3437/4885P2RX7 4386/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | TRPV4 4738/4885CETP 3437/4885P2RX7 4386/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | TRPV4 4738/4885CETP 3437/4885P2RX7 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.